# Social impact bonds that fund biosimilar switching, repaid from payer savings

Source: https://onco.cc/ideas/idea-reg-social-impact-bond-switching/  
OnCo record `idea-reg-social-impact-bond-switching` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Hospitals often lack the staff to switch patients to cheaper equivalent drugs. Private investors could fund the switching teams and be repaid by the health system from the money saved.

## Summary

Switching programmes (pharmacists, patient information, prescribing system changes) return far more in drug savings than they cost, but compete for scarce operating budgets. A social impact bond raises private capital to fund the programme and repays investors, with a return, from verified savings measured against a pre-agreed baseline; the payer pays only if savings materialise. Social impact bonds have been used in social care and public health; oncology drug switching has an unusually measurable outcome.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Bond-funded switching programmes achieve biosimilar and generic shares above 85% within a year and generate verified savings at least five times the programme cost, with investors repaid in full.
- Rationale: The savings from switching are large, fast and measurable from claims data, which is exactly the profile that makes outcome-based financing work; the constraint is up-front capacity, which the bond supplies.
- Proposed test: Structure one bond covering ten hospitals for two new oncology biosimilar launches, with an independent evaluator verifying savings, and publish the returns and clinical safety data.
- Maturity: speculative
- Actor: philanthropy

## Sources

- Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017): https://doi.org/10.1038/nrclinonc.2017.31

## Connected records

- bottlenecks: [Funding follows fashion, not burden](https://onco.cc/bottlenecks/b-funding-allocation/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)
- key papers: [The high price of anticancer drugs: origins, implications, barriers, solutions](https://onco.cc/key-papers/paper-prasad-nat-rev-clin-oncol/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-social-impact-bond-switching.json